Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
topped up again to day looking for good recovery over the next two years , management payout when the sp reaches £8 a share!!! fingers crossed
sold half my holding when the covid hit after a drop of 5%
just bought back today.
great long term - so difficult picking the bottom but a lot of things falling into place
better testing
better drugs to at least reduce the severity of the virus
shame the lock down happened as less than 1 % of the population effected and the lock down has or will have put 1000's out of work and flattered the chances of a quick recovery.fear and more fear politicians not prepared to stand up against.
now school opening with all the books roped off !!! shame common sense has been lost.
my worry I am down 35% overall on pfc ,but this could move so fast to 400 so playing it in the short term for me is risky
prefer to add small amounts over the next couple of months and hold for longer term dividends.
By Roxanne Liu and Makiko Yamazaki
TOKYO/BEIJING (Reuters) - Shares in Japan's Fujifilm Holdings Corp surged 15% on Wednesday after a Chinese official said an active ingredient of the company's Avigan anti-flu drug appeared to help coronavirus patients recover.
Avigan, also known as Favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014.
Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.
But a Fujifilm spokesman said the company expects no direct earnings impact from potential sales growth of Favipiravir in China, at least for now, as its license for the key ingredient in the country already expired last year.
In Japan, Fujifilm manufactures Avigan only on receiving orders from the government and has no sales target for the drug, she said.
Fujifilm shares closed Wednesday up 15.4% at their daily limit high of 5,238 yen.
In a clinical trial in Shenzhen involving 80 participants, patients who took Favipiravir showed greater chest improvement and took less time to test negative for the genomic trace of the virus, compared with patients not given the drug, Zhang said.
First developed by Fujifilm Toyama Chemical Co Ltd, the drug has been approved for manufacturing in China by Zhejiang Hisun Pharmaceutical Co Ltd for use against new or recurring influenza in adults, the Chinese drugmaker said in a filing last month.
In 2016, the Japanese government supplied Favipiravir as an emergency aid to counter the Ebola virus outbreak in Guinea.
(Reporting by Tomo Uetake in Sydney, Roxanne Liu in Beijing and Makiko Yamazaki in Tokyo; Writing by Elaine Lies in Tokyo; Editing by Tom Hogue, Kenneth Maxwell and Raissa Kasolowsky)
Plus500 seeing big increase in demand would have expected ptec to be impacted in a positive way
They say not strange?!
bought 900 shares , cnbc had a view 4 months hit 4 months recovery, so difficult picking a bottom , feel its going to get a lot worse before it gets better but happy to hold for 5-10 years and accept the dividends so topped up will do again next month
with the buy back will top up and hold
topped up happy to hold for the long term and accept the great dividends!!!
will buy more on weakness of sp